Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca, Optimer Pharma target C. diff in South America
January 2013
SHARING OPTIONS:

JERSEY CITY, N.J.Optimer Pharmaceuticals has announced an exclusive agreement with AstraZeneca PLC for the commercialization of fidaxomicin tablets to treat Clostridium difficile infection in South America, including Brazil, Mexico, Central America and the Caribbean. AstraZeneca will be responsible for commercialization and will pay Optimer $1 million upfront, up to $3 million in milestones based on first commercial sales in select countries and up to an additional $19 million in other milestones if other sales-related goals are met.

"C. difficile infection is a global problem, and this collaboration further advances our plans to make fidaxomicin available to patients in need globally," said Pedro Lichtinger, Optimer's president and CEO. "AstraZeneca has the infrastructure and expertise to commercialize fidaxomicin in the diverse range of countries that make up Central and South America, and they will be a strong partner moving forward."


 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.